Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic
defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns
upper airway mucosa. It leads to retention of secretions and consecutive chronic
inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and
throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial
aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic
saline with respect to ENT-related quality of life which is influenced by mucus retention
and the resulting inflammation.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005574
  •   2014/04/02
  •   2010/03/12
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01086839  (
  •   NaCl 6.0%-nasal-CF  (University of Jena)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Cystic Fibrosis
  •   Rhinosinusitis
  •   J32 -  Chronic sinusitis
  •   E84 -  Cystic fibrosis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: sodium chloride 6%
  •   Drug: sodium chloride 0,9%
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo
  •   Treatment
  •   Crossover
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Changes in the Sino-nasal-outcome test SNOT-20 adapt CF; time frame: days 1, 29, 57 and 85

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Changes in the nasal lavage fluid and in the serological markers of inflammation; time frame: days 1, 29, 57 and 85

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2010/03/31
  •   69
  •   Multicenter trial
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   8   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Subject has a confirmed diagnosis of cystic fibrosis based on: 2 positive sweat
chloride tests and/or genetic characterization

- Subject is 8 years of age or older

- informed consent of the patient or legal representative

- Women of childbearing potential are only included into the study, if they are using
an effective method of birth control during the protocol (failure rate <1% e.g.
implants, combined oral contraceptives, injectables, some intrauterine devices,
sexual abstinence or vasectomised partner)

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Subject has no chronic rhinosinusitis (European Position Paper on Rhinosinusitis and
Nasal Polyps (EPOS-criteria)

- Subject has a critical condition defined as: forced expiratory volume at one second
< 30% and / or arterial oxygen saturation < 93% without O2-substitution; need of

- Subject had an ENT surgery within 6 months prior to study

- Subject participates in another clinical trial within 30 days prior to study entry

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • University of Jena
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University of Jena
    • Jochen Mainz, M.D. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Jochen G Mainz, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cyst Fibros. 2009 Jun;8 Suppl 1:S10-4.; 19460681
  •   Mainz JG, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, Schneider G, Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax. 2009 Jun;64(6):535-40. Epub 2009 Mar 11.; 19282318
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   1
  •   2013/12/01
* This entry means the parameter is not applicable or has not been set.